Date:__2023-11-10___

Your Name: ___Dan Sun___

Manuscript Title:_____Developing and validating a prediction model of live birth in patients with moderate-to-severe intrauterine adhesions: A new approach by endometrial morphology measurement by 3D transvaginal ultrasound______

Manuscript number (if known):___QIMS-23-1014-R1_____

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | Yes | Hunan Provincial Clinical Medical Technology Innovation Guiding Project (Nos. 2021SK53704 and. 2021SK53711) Natural Science Foundation of Hunan Province (Nos. 2021JJ40956 and 2020JJ4859) Key Research and Development Program of Hunan province (No. 2022SK2033) |
| | | Time frame: past | Hunan Science and Technology Department (No. 2020 SK4017) |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | None | |
| 3 | Royalties or licenses | √None | |
| 4 | Consulting fees | √None | |

| 5 | Payment or honoraria for | √None | |
|----|--|---------|--|
| | lectures, presentations, speakers bureaus, | | |
| | manuscript writing or | | |
| | educational events | | |
| 6 | Payment for expert | None | |
| | testimony | | |
| 7 | Support for attending | | |
| / | Support for attending meetings and/or travel | _ √None | |
| | <i></i> | | |
| | | | |
| 8 | Patents planned, issued or | _√None | |
| | pending | | |
| | | | |
| 9 | Participation on a Data | _√None | |
| | Safety Monitoring Board or Advisory Board | | |
| 10 | Leadership or fiduciary role | √ None | |
| 10 | in other board, society, | | |
| | committee or advocacy | | |
| | group, paid or unpaid | | |
| 11 | Stock or stock options | _√None | |
| | | | |
| 12 | Dessint of any immedia | | |
| 12 | Receipt of equipment, materials, drugs, medical | None | |
| | writing, gifts or other | | |
| | services | | |
| 13 | Other financial or non- | √None | |
| | financial interests | | |
| | | | |

This study was supported by the Hunan Provincial Clinical Medical Technology Innovation Guiding Project (Nos. 2021SK53704 and 2021SK53711), the Natural Science Foundation of Hunan Province (Nos. 2021JJ40956 and 2020JJ4859), the Key Research and Development Program of Hunan province (No. 2022SK2033), and the Hunan Science and Technology Department (No. 2020 SK4017).

Please place an "X" next to the following statement to indicate your agreement:

Date: __2023-11-10______ Your Name: ___Shuijing Yi_____ Manuscript Title: ____Developing and validating a prediction model of live birth in patients with moderate-to-severe intrauterine adhesions: A new approach by endometrial morphology measurement by 3D transvaginal ultrasound

Manuscript number (if known):____QIMS-23-1014-R1_____

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this | Specifications/Comments (e.g., if payments were made to you or to your |
|---|-------------------------------|---|---|
| | | relationship or indicate | institution) |
| | | none (add rows as | |
| | | needed) | |
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present | Yes | Hunan Provincial Clinical Medical Technology Innovation |
| | manuscript (e.g., funding, | | Guiding Project (Nos. 2021SK53704 and. 2021SK53711) |
| | provision of study materials, | | Natural Science Foundation of Hunan Province (Nos. |
| | medical writing, article | | 2021JJ40956 and 2020JJ4859) |
| | processing charges, etc.) | | Key Research and Development Program of Hunan |
| | No time limit for this item. | | province (No. 2022SK2033) |
| | | | Hunan Science and Technology Department (No. 2020 |
| | | | SK4017) |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | √None | |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | √None | |
| | | | |
| | | | |
| 4 | Consulting fees | √None | |
| | | | |

| 5 | Payment or honoraria for | √None | |
|----|--|---------|--|
| | lectures, presentations, speakers bureaus, | | |
| | manuscript writing or | | |
| | educational events | | |
| 6 | Payment for expert | None | |
| | testimony | | |
| 7 | Support for attending | | |
| / | Support for attending meetings and/or travel | _ √None | |
| | <i></i> | | |
| | | | |
| 8 | Patents planned, issued or | _√None | |
| | pending | | |
| | | | |
| 9 | Participation on a Data | _√None | |
| | Safety Monitoring Board or Advisory Board | | |
| 10 | Leadership or fiduciary role | √ None | |
| 10 | in other board, society, | | |
| | committee or advocacy | | |
| | group, paid or unpaid | | |
| 11 | Stock or stock options | _√None | |
| | | | |
| 12 | Dessint of any immedia | | |
| 12 | Receipt of equipment, materials, drugs, medical | None | |
| | writing, gifts or other | | |
| | services | | |
| 13 | Other financial or non- | √None | |
| | financial interests | | |
| | | | |

This study was supported by the Hunan Provincial Clinical Medical Technology Innovation Guiding Project (Nos. 2021SK53704 and 2021SK53711), the Natural Science Foundation of Hunan Province (Nos. 2021JJ40956 and 2020JJ4859), the Key Research and Development Program of Hunan province (No. 2022SK2033), and the Hunan Science and Technology Department (No. 2020 SK4017).

Please place an "X" next to the following statement to indicate your agreement:

Date:__2023-11-10_____ Your Name:___Fei Zeng_____

Manuscript Title:_____Developing and validating a prediction model of live birth in patients with moderate-to-severe intrauterine adhesions: A new approach by endometrial morphology measurement by 3D transvaginal ultrasound______

Manuscript number (if known):___QIMS-23-1014-R1_____

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|--|
| | | needed) Time frame: Since the initial | planning of the work |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, | Yes | Hunan Provincial Clinical Medical Technology Innovation Guiding Project (Nos. 2021SK53704 and. 2021SK53711) Natural Science Foundation of Hunan Province (Nos. |
| | medical writing, article processing charges, etc.) No time limit for this item. | | 2021JJ40956 and 2020JJ4859) Key Research and Development Program of Hunan province (No. 2022SK2033) |
| | | | Hunan Science and Technology Department (No. 2020 SK4017) |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | √None | |
| 3 | Royalties or licenses | √None | |
| 4 | Consulting fees | √None | |

| 5 | Payment or honoraria for | √None | |
|----|--|---------|--|
| | lectures, presentations, speakers bureaus, | | |
| | manuscript writing or | | |
| | educational events | | |
| 6 | Payment for expert | None | |
| | testimony | | |
| 7 | Support for attending | | |
| / | Support for attending meetings and/or travel | _ √None | |
| | <i></i> | | |
| | | | |
| 8 | Patents planned, issued or | _√None | |
| | pending | | |
| | | | |
| 9 | Participation on a Data | _√None | |
| | Safety Monitoring Board or Advisory Board | | |
| 10 | Leadership or fiduciary role | √ None | |
| 10 | in other board, society, | | |
| | committee or advocacy | | |
| | group, paid or unpaid | | |
| 11 | Stock or stock options | _√None | |
| | | | |
| 12 | Dessint of any immedia | | |
| 12 | Receipt of equipment, materials, drugs, medical | None | |
| | writing, gifts or other | | |
| | services | | |
| 13 | Other financial or non- | √None | |
| | financial interests | | |
| | | | |

This study was supported by the Hunan Provincial Clinical Medical Technology Innovation Guiding Project (Nos. 2021SK53704 and 2021SK53711), the Natural Science Foundation of Hunan Province (Nos. 2021JJ40956 and 2020JJ4859), the Key Research and Development Program of Hunan province (No. 2022SK2033), and the Hunan Science and Technology Department (No. 2020 SK4017).

Please place an "X" next to the following statement to indicate your agreement:

Date:__2023-11-10___

Your Name:___Wenwei Cheng_

Manuscript Title:_____Developing and validating a prediction model of live birth in patients with moderate-to-severe intrauterine adhesions: A new approach by endometrial morphology measurement by 3D transvaginal ultrasound______

Manuscript number (if known):___QIMS-23-1014-R1___

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | Yes | Hunan Provincial Clinical Medical Technology Innovation Guiding Project (Nos. 2021SK53704 and. 2021SK53711) Natural Science Foundation of Hunan Province (Nos. 2021JJ40956 and 2020JJ4859) Key Research and Development Program of Hunan province (No. 2022SK2033) |
| | | Time frame: past | Hunan Science and Technology Department (No. 2020 SK4017) |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | None | |
| 3 | Royalties or licenses | √None | |
| 4 | Consulting fees | √None | |

| 5 | Payment or honoraria for lectures, presentations, | √None | |
|----|--|--------|--|
| | | | |
| | speakers bureaus, manuscript writing or | | |
| | educational events | | |
| 6 | Payment for expert | √None | |
| | testimony | | |
| | | | |
| 7 | Support for attending meetings and/or travel | _ | |
| | J | | |
| | | | |
| 8 | Patents planned, issued or | _√None | |
| | pending | | |
| | | | |
| 9 | Participation on a Data | _√None | |
| | Safety Monitoring Board or Advisory Board | | |
| 10 | | | |
| 10 | Leadership or fiduciary role in other board, society, | None | |
| | committee or advocacy | | |
| | group, paid or unpaid | | |
| 11 | Stock or stock options | _√None | |
| | | | |
| | | | |
| 12 | Receipt of equipment, | None | |
| | materials, drugs, medical writing, gifts or other | | |
| | services | | |
| 13 | Other financial or non- | √None | |
| | financial interests | | |
| | | | |

This study was supported by the Hunan Provincial Clinical Medical Technology Innovation Guiding Project (Nos. 2021SK53704 and 2021SK53711), the Natural Science Foundation of Hunan Province (Nos. 2021JJ40956 and 2020JJ4859), the Key Research and Development Program of Hunan province (No. 2022SK2033), and the Hunan Science and Technology Department (No. 2020 SK4017).

Please place an "X" next to the following statement to indicate your agreement:

Date:__2023-11-10_____

Your Name:___Dabao Xu__

Manuscript Title:_____Developing and validating a prediction model of live birth in patients with moderate-to-severe intrauterine adhesions: A new approach by endometrial morphology measurement by 3D transvaginal ultrasound______

Manuscript number (if known):___QIMS-23-1014-R1____

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with | Specifications/Comments |
|---|-------------------------------|-------------------------------|---|
| | | whom you have this | (e.g., if payments were made to you or to your |
| | | relationship or indicate | institution) |
| | | none (add rows as | |
| | | needed) | |
| | | Time frame: Since the initial | planning of the work |
| 1 | All support for the present | Yes | Hunan Provincial Clinical Medical Technology Innovation |
| | manuscript (e.g., funding, | | Guiding Project (Nos. 2021SK53704 and. 2021SK53711) |
| | provision of study materials, | | Natural Science Foundation of Hunan Province (Nos. |
| | medical writing, article | | 2021JJ40956 and 2020JJ4859) |
| | processing charges, etc.) | | Key Research and Development Program of Hunan |
| | No time limit for this item. | | province (No. 2022SK2033) |
| | | | Hunan Science and Technology Department (No. 2020 |
| | | | SK4017) |
| | | Time frame: past | 36 months |
| 2 | Grants or contracts from | √None | |
| | any entity (if not indicated | | |
| | in item #1 above). | | |
| 3 | Royalties or licenses | √None | |
| | | | |
| | | | |
| 4 | Consulting fees | √None | |
| | | | |

| 5 | Payment or honoraria for | √None | |
|----|--|---------|--|
| | lectures, presentations, speakers bureaus, | | |
| | manuscript writing or | | |
| | educational events | | |
| 6 | Payment for expert | None | |
| | testimony | | |
| 7 | Support for attending | | |
| / | Support for attending meetings and/or travel | _ √None | |
| | <i></i> | | |
| | | | |
| 8 | Patents planned, issued or | _√None | |
| | pending | | |
| | | | |
| 9 | Participation on a Data | _√None | |
| | Safety Monitoring Board or Advisory Board | | |
| 10 | Leadership or fiduciary role | √ None | |
| 10 | in other board, society, | | |
| | committee or advocacy | | |
| | group, paid or unpaid | | |
| 11 | Stock or stock options | _√None | |
| | | | |
| 12 | Dessint of any immedia | | |
| 12 | Receipt of equipment, materials, drugs, medical | None | |
| | writing, gifts or other | | |
| | services | | |
| 13 | Other financial or non- | √None | |
| | financial interests | | |
| | | | |

This study was supported by the Hunan Provincial Clinical Medical Technology Innovation Guiding Project (Nos. 2021SK53704 and 2021SK53711), the Natural Science Foundation of Hunan Province (Nos. 2021JJ40956 and 2020JJ4859), the Key Research and Development Program of Hunan province (No. 2022SK2033), and the Hunan Science and Technology Department (No. 2020 SK4017).

Please place an "X" next to the following statement to indicate your agreement:

Date:__2023-11-10___

Your Name:____Xingping Zhao_

Manuscript Title:_____Developing and validating a prediction model of live birth in patients with moderate-to-severe intrauterine adhesions: A new approach by endometrial morphology measurement by 3D transvaginal ultrasound______

Manuscript number (if known):___QIMS-23-1014-R1___

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|---|--|---|---|
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | Yes | Hunan Provincial Clinical Medical Technology Innovation Guiding Project (Nos. 2021SK53704 and. 2021SK53711) Natural Science Foundation of Hunan Province (Nos. 2021JJ40956 and 2020JJ4859) Key Research and Development Program of Hunan province (No. 2022SK2033) |
| | | Time frame: past | Hunan Science and Technology Department (No. 2020 SK4017) |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | None | |
| 3 | Royalties or licenses | √None | |
| 4 | Consulting fees | √None | |

| 5 | Payment or honoraria for lectures, presentations, | √None | |
|----|--|--------|--|
| | | | |
| | speakers bureaus, manuscript writing or | | |
| | educational events | | |
| 6 | Payment for expert | √None | |
| | testimony | | |
| | | | |
| 7 | Support for attending meetings and/or travel | _ | |
| | J | | |
| | | | |
| 8 | Patents planned, issued or | _√None | |
| | pending | | |
| | | | |
| 9 | Participation on a Data | _√None | |
| | Safety Monitoring Board or Advisory Board | | |
| 10 | | | |
| 10 | Leadership or fiduciary role in other board, society, | None | |
| | committee or advocacy | | |
| | group, paid or unpaid | | |
| 11 | Stock or stock options | _√None | |
| | | | |
| | | | |
| 12 | Receipt of equipment, | None | |
| | materials, drugs, medical writing, gifts or other | | |
| | services | | |
| 13 | Other financial or non- | √None | |
| | financial interests | | |
| | | | |

This study was supported by the Hunan Provincial Clinical Medical Technology Innovation Guiding Project (Nos. 2021SK53704 and 2021SK53711), the Natural Science Foundation of Hunan Province (Nos. 2021JJ40956 and 2020JJ4859), the Key Research and Development Program of Hunan province (No. 2022SK2033), and the Hunan Science and Technology Department (No. 2020 SK4017).

Please place an "X" next to the following statement to indicate your agreement: